BIIB-061
- Generic Name
- BIIB-061
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
Phase 2
Withdrawn
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Biogen
- Registration Number
- NCT04079088
Single-Dose Study of a New Formulation of BIIB061
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Biogen
- Target Recruit Count
- 8
- Registration Number
- NCT02521545
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers
- First Posted Date
- 2014-08-29
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Biogen
- Target Recruit Count
- 56
- Registration Number
- NCT02228707
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2015-02-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 39
- Registration Number
- NCT02071121
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath